HPC4
MCID: PRS135
MIFTS: 22

Prostate Cancer, Hereditary, 4 (HPC4)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer, Hereditary, 4

MalaCards integrated aliases for Prostate Cancer, Hereditary, 4:

Name: Prostate Cancer, Hereditary, 4 57 13 72
Prostate Cancer, Hereditary, on Chromosome 7 57
Prostate Cancer, Susceptibility to, 4 57
Prostate Cancer 4 57
Hpc4 57

Classifications:



External Ids:

OMIM 57 608658
MedGen 42 C1837593
UMLS 72 C1837593

Summaries for Prostate Cancer, Hereditary, 4

MalaCards based summary : Prostate Cancer, Hereditary, 4, also known as prostate cancer, hereditary, on chromosome 7, is related to prostate cancer. An important gene associated with Prostate Cancer, Hereditary, 4 is HPC4 (Prostate Cancer, Hereditary, 4). The drugs 4-Aminopyridine and Potassium Channel Blockers have been mentioned in the context of this disorder. Affiliated tissues include prostate, t cells and lung.

Wikipedia : 75 Prostate cancer, hereditary, 4 is a protein that in humans is encoded by the HPC4... more...

More information from OMIM: 608658

Related Diseases for Prostate Cancer, Hereditary, 4

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 4

Clinical features from OMIM:

608658

Drugs & Therapeutics for Prostate Cancer, Hereditary, 4

Drugs for Prostate Cancer, Hereditary, 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 8)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 4 504-24-5 1727
2 Potassium Channel Blockers Phase 4
3
Choline Approved, Nutraceutical Phase 3 62-49-7 305
4 Gastrointestinal Agents Phase 3
5 Nootropic Agents Phase 3
6 Lipid Regulating Agents Phase 3
7 Hypolipidemic Agents Phase 3
8 Antimetabolites Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy Not yet recruiting NCT03701581 Phase 4 4-Aminopyridine
2 Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities Completed NCT02260817 Phase 3 11C-choline Injection
3 A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles After Pelvic Lymphadenectomy in Women With Gynecologic Malignancies: a Randomized Clinical Trial Completed NCT01470677 Phase 3 Tachosil fibrin patch
4 A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma. Completed NCT00432107 Phase 2 APO866
5 A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma Completed NCT00431912 Phase 2 APO866

Search NIH Clinical Center for Prostate Cancer, Hereditary, 4

Genetic Tests for Prostate Cancer, Hereditary, 4

Anatomical Context for Prostate Cancer, Hereditary, 4

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 4:

41
Prostate, T Cells, Lung, Testes, Breast

Publications for Prostate Cancer, Hereditary, 4

Articles related to Prostate Cancer, Hereditary, 4:

(show top 50) (show all 51)
# Title Authors PMID Year
1
Multiple newly identified loci associated with prostate cancer susceptibility. 8
18264097 2008
2
Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. 8
14769943 2004
3
Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. 38
31077523 2019
4
Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma. 38
31140181 2019
5
Characterization of the Recommendations in the Choosing Wisely Initiative. 38
30345804 2019
6
Prostate cancer detection using quantitative T2 and T2 -weighted imaging: The effects of 5-alpha-reductase inhibitors in men on active surveillance. 38
29135073 2018
7
Gambogic Acid Induces Cell Apoptosis and Inhibits MAPK Pathway in PTEN-/-/p53-/- Prostate Cancer Cells In Vitro and Ex Vivo. 38
28578487 2018
8
The Efficacy of Transrectal Ultrasound Guided Biopsy Versus Transperineal Template Biopsy of the Prostate in Diagnosing Prostate Cancer in Men with Previous Negative Transrectal Ultrasound Guided Biopsy. 38
28299763 2017
9
Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA. 38
28039477 2017
10
Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD. 38
27493267 2017
11
Non-Prostate-Specific Membrane Antigen-Avid Metastatic Lung Nodule From Primary Prostatic Adenocarcinoma. 38
27556788 2016
12
Simultaneous PET/MRI vs PET/CT in oncology. A systematic review. 38
27424217 2016
13
[Mechanisms of castration resistance: Intratumoral hypoxia stimulates the androgen receptor expression]. 38
26896427 2016
14
Lung Cancer and Multiple Neoplasms: A Retrospective Analysis. 38
26987325 2016
15
Prostate cancer: 4 big questions. 38
26672789 2015
16
[On "2015 Guidelines for Prevention and Treatment of Osteoporosis". Osteoporosis associated with sex hormone depletion treatment]. 38
26320536 2015
17
Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer. 38
25351792 2015
18
The epidemiology of cancer in Angola-results from the cancer registry of the national oncology centre of Luanda, Angola. 38
25729423 2015
19
Adherence to Mediterranean diet and risk of cancer: a systematic review and meta-analysis of observational studies. 38
24599882 2014
20
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. 38
25163905 2014
21
Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. 38
24081977 2013
22
Genetic testing in the European Union: does economic evaluation matter? 38
21598012 2012
23
Stomach metastasis in a patient with prostate cancer 4 years after the initial diagnosis: a case report and a literature review. 38
23243531 2012
24
Overdiagnosis of a typical carcinoid tumor as an adenocarcinoma of the lung: a case report and review of the literature. 38
22269186 2012
25
Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis. 38
23074405 2010
26
Effects of interval between diagnosis and time of survey upon preferred information format for prostate cancer patients. 38
19527371 2009
27
Defining increased future risk for prostate cancer: evidence from a population based screening cohort. 38
19012915 2009
28
[Antioxidant power and cellular damage in prostate cancer]. 38
18709810 2008
29
What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer: 4-weeks-post-treatment depressive symptoms or type of treatment? 38
17091363 2007
30
Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. 38
17122505 2006
31
Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. 38
17001156 2006
32
Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made. 38
16983114 2006
33
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. 38
16899616 2006
34
Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. 38
16611404 2006
35
Therapeutic targeting of prostate cancer. 38
15539935 2004
36
Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. 38
14973081 2004
37
Ethnic differences in quality of life among early breast and prostate cancer survivors. 38
11921326 2002
38
Changes in natural killer cell activity by external radiotherapy and/or brachytherapy. 38
11836608 2002
39
[Ultrasound-guided biopsy: screening of prostate cancer with a single set of 14 systematic biopsies]. 38
11221051 2000
40
[RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients]. 38
10086262 1999
41
Prostate cancer: 4. Screening. 38
9834724 1998
42
Insulin-like growth factors and prostate cancer. 38
10453282 1998
43
[Study on the quality of life in patients with prostate cancer]. 38
9812508 1997
44
Cancer mortality among pulp and paper workers in Poland. A cohort study. 38
9187043 1997
45
Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate. 38
9436285 1997
46
Combined finasteride and flutamide therapy in men with advanced prostate cancer. 38
8973674 1996
47
[Screening of cancer of the prostate: study in a Spanish population]. 38
8929102 1996
48
Update on urology--prostate cancer. 4--Treatment of local disease. 38
8631420 1995
49
[Studies on 5-FU concentration in serum and prostate cancer tissue after oral administration of UFT]. 38
1927771 1991
50
Ultrasound of the prostate--applications and indications. 38
2024104 1991

Variations for Prostate Cancer, Hereditary, 4

Expression for Prostate Cancer, Hereditary, 4

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 4.

Pathways for Prostate Cancer, Hereditary, 4

GO Terms for Prostate Cancer, Hereditary, 4

Sources for Prostate Cancer, Hereditary, 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....